140 related articles for article (PubMed ID: 21091042)
21. The Janus Kinase 2 (JAK2) V617F mutation in hematological malignancies in México.
Ruiz-Argüelles GJ; Garcés-Eisele J; Reyes-Núñez V; Ruiz-Delgado GJ; Navarro-Vázquez M; González-Carrillo ML
Rev Invest Clin; 2006; 58(5):458-61. PubMed ID: 17408106
[TBL] [Abstract][Full Text] [Related]
22. Mutations and chromosomal rearrangements of JAK2: not only a myeloid issue.
Salmoiraghi S; Montalvo ML; D'Agostini E; Amicarelli G; Minnucci G; Spinelli O; Rambaldi A
Expert Rev Hematol; 2013 Aug; 6(4):429-39. PubMed ID: 23991929
[TBL] [Abstract][Full Text] [Related]
23. Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity.
Liu PC; Caulder E; Li J; Waeltz P; Margulis A; Wynn R; Becker-Pasha M; Li Y; Crowgey E; Hollis G; Haley P; Sparks RB; Combs AP; Rodgers JD; Burn TC; Vaddi K; Fridman JS
Clin Cancer Res; 2009 Nov; 15(22):6891-900. PubMed ID: 19887489
[TBL] [Abstract][Full Text] [Related]
24. Sustained Response to Ruxolitinib of Eosinophilia-Associated Myeloproliferative Neoplasm with Translocation t(8;9)(p21;p24).
Cai P; Liu S; Duan L; Huo L; Wu D; Chen S; Yang R; Yang X
Acta Haematol; 2023; 146(5):397-400. PubMed ID: 37562364
[TBL] [Abstract][Full Text] [Related]
25. The G allele of the JAK2 rs10974944 SNP, part of JAK2 46/1 haplotype, is strongly associated with JAK2 V617F-positive myeloproliferative neoplasms.
Trifa AP; Cucuianu A; Petrov L; Urian L; Militaru MS; Dima D; Pop IV; Popp RA
Ann Hematol; 2010 Oct; 89(10):979-83. PubMed ID: 20422415
[TBL] [Abstract][Full Text] [Related]
26. JAK/STAT signal transduction: regulators and implication in hematological malignancies.
Valentino L; Pierre J
Biochem Pharmacol; 2006 Mar; 71(6):713-21. PubMed ID: 16426581
[TBL] [Abstract][Full Text] [Related]
27. JAK2 V617F/C618R mutation in a patient with polycythemia vera: a case study and review of the literature.
Yoo JH; Park TS; Maeng HY; Sun YK; Kim YA; Kie JH; Cho EH; Song J; Lee KA; Suh B; Choi JR
Cancer Genet Cytogenet; 2009 Feb; 189(1):43-7. PubMed ID: 19167611
[TBL] [Abstract][Full Text] [Related]
28. Identification of a MYO18A-PDGFRB fusion gene in an eosinophilia-associated atypical myeloproliferative neoplasm with a t(5;17)(q33-34;q11.2).
Walz C; Haferlach C; Hänel A; Metzgeroth G; Erben P; Gosenca D; Hochhaus A; Cross NC; Reiter A
Genes Chromosomes Cancer; 2009 Feb; 48(2):179-83. PubMed ID: 19006078
[TBL] [Abstract][Full Text] [Related]
29. [Molecular mechanisms in myeloproliferative diseases and myelodysplastic syndromes].
Harada H; Harada Y; Kimura A
Nihon Rinsho; 2009 Oct; 67(10):1901-5. PubMed ID: 19860187
[TBL] [Abstract][Full Text] [Related]
30. JAK2 mutations and clinical practice in myeloproliferative neoplasms.
Tefferi A
Cancer J; 2007; 13(6):366-71. PubMed ID: 18032973
[TBL] [Abstract][Full Text] [Related]
31. Jak2 inhibitors: rationale and role as therapeutic agents in hematologic malignancies.
Sayyah J; Sayeski PP
Curr Oncol Rep; 2009 Mar; 11(2):117-24. PubMed ID: 19216843
[TBL] [Abstract][Full Text] [Related]
32. New insights into the pathogenesis of JAK2 V617F-positive myeloproliferative disorders and consequences for the management of patients.
Villeval JL; James C; Pisani DF; Casadevall N; Vainchenker W
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):341-51. PubMed ID: 16810610
[TBL] [Abstract][Full Text] [Related]
33. Janus kinase 2 mutations in Philadelphia negative chronic myeloproliferative disorders: clinical implications.
Panani AD
Cancer Lett; 2009 Oct; 284(1):7-14. PubMed ID: 19269737
[TBL] [Abstract][Full Text] [Related]
34. JAK2 V617F: implications for thrombosis in myeloproliferative diseases.
Hexner EO
Curr Opin Hematol; 2007 Sep; 14(5):450-4. PubMed ID: 17934351
[TBL] [Abstract][Full Text] [Related]
35. Kinase drug discovery approaches in chronic myeloproliferative disorders.
Kumar C; Purandare AV; Lee FY; Lorenzi MV
Oncogene; 2009 Jun; 28(24):2305-13. PubMed ID: 19421140
[TBL] [Abstract][Full Text] [Related]
36. A t(8;9) translocation with PCM1-JAK2 fusion in a patient with T-cell lymphoma.
Adélaïde J; Pérot C; Gelsi-Boyer V; Pautas C; Murati A; Copie-Bergman C; Imbert M; Chaffanet M; Birnbaum D; Mozziconacci MJ
Leukemia; 2006 Mar; 20(3):536-7. PubMed ID: 16424865
[No Abstract] [Full Text] [Related]
37. Myelodysplastic syndrome with t(9;22)(p24;q11.2), a BCR-JAK2 fusion: case report and review of the literature.
Kantarcioglu B; Kaygusuz-Atagunduz I; Uzay A; Toptas T; Tuglular TF; Bayik M
Int J Hematol; 2015 Sep; 102(3):383-7. PubMed ID: 25833723
[TBL] [Abstract][Full Text] [Related]
38. [Development of tyrosine kinase inhibitors for hematologic neoplasms. FLT3 and JAK2 as therapeutic targets].
Lipka D; Heidel F; Huber C; Fischer T
Pharm Unserer Zeit; 2008; 37(5):394-403. PubMed ID: 18729264
[No Abstract] [Full Text] [Related]
39. Should myeloid and lymphoid neoplasms with PCM1-JAK2 and other rearrangements of JAK2 be recognized as specific entities?
Bain BJ; Ahmad S
Br J Haematol; 2014 Sep; 166(6):809-17. PubMed ID: 24913195
[TBL] [Abstract][Full Text] [Related]
40. [Towards better understanding of hematolymphoid malignancies--based on the WHO-2008 classification: summary].
Tohyama K
Rinsho Byori; 2011 May; 59(5):502-3. PubMed ID: 21706866
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
